<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We determined the contribution to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> of the PH domain leucine-rich repeat protein phosphatase (PHLPP), which dephosphorylates Akt at Ser473, inhibiting its activity </plain></SENT>
<SENT sid="1" pm="."><plain>We measured the abundance of PHLPP in fat and skeletal muscle from <z:mp ids='MP_0001261'>obese</z:mp> participants </plain></SENT>
<SENT sid="2" pm="."><plain>To study the effect of PHLPP on insulin signalling, PHLPP (also known as PHLPP1) was overexpressed in HepG2 and L6 cells </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Subcutaneous fat samples were obtained from 82 morbidly <z:mp ids='MP_0001261'>obese</z:mp> and ten non-<z:mp ids='MP_0001261'>obese</z:mp> participants </plain></SENT>
<SENT sid="4" pm="."><plain>Skeletal muscle samples were obtained from 12 <z:mp ids='MP_0001261'>obese</z:mp> and eight non-<z:mp ids='MP_0001261'>obese</z:mp> participants </plain></SENT>
<SENT sid="5" pm="."><plain>Quantification of PHLPP-1 in human tissues was performed by immunoblotting </plain></SENT>
<SENT sid="6" pm="."><plain>The functional consequences of recombinant PHLPP1 overexpression in <z:e sem="disease" ids="C0019204" disease_type="Neoplastic Process" abbrv="">hepatoma</z:e> HepG2 cells and L6 myoblasts were investigated </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Of the 82 <z:mp ids='MP_0001261'>obese</z:mp> participants, 31 had <z:mpath ids='MPATH_458'>normal</z:mpath> fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>, 33 impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> and 18 type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>PHLPP-1 abundance was twofold higher in the three <z:mp ids='MP_0001261'>obese</z:mp> groups than in non-<z:mp ids='MP_0001261'>obese</z:mp> participants (p = 0.004) </plain></SENT>
<SENT sid="9" pm="."><plain>No differences were observed between <z:mp ids='MP_0001261'>obese</z:mp> participants with <z:mpath ids='MPATH_458'>normal</z:mpath> fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>, impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>PHLPP-1 abundance was correlated with basal Akt Ser473 phosphorylation (r = -0.48; p = 0.001), BMI (r = 0.44; p &lt; 0.0001), insulin (r = 0.35; p &lt; 0.0001) and HOMA (r = 0.38; p &lt; 0.0001) </plain></SENT>
<SENT sid="11" pm="."><plain>PHLPP-1 abundance was twofold higher in the skeletal muscle of 12 <z:mp ids='MP_0001261'>obese</z:mp> participants than in that of eight non-<z:mp ids='MP_0001261'>obese</z:mp> participants (p &lt; 0.0001) </plain></SENT>
<SENT sid="12" pm="."><plain>Insulin treatment of HepG2 cells resulted in a dose- and time-dependent upregulation of PHLPP-1 </plain></SENT>
<SENT sid="13" pm="."><plain>Overexpression of PHLPP1 in HepG2 cells and L6 myoblasts resulted in impaired insulin signalling involving Akt/<z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase kinase 3, <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthesis and <z:chebi fb="105" ids="17234">glucose</z:chebi> transport </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS/INTERPRETATION: Increased abundance of PHLPP-1, production of which is regulated by insulin, may represent a new molecular defect in insulin-resistant states such as <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
</text></document>